Alfred Garfall, MD, discusses updated safety and efficacy data from a phase I trial evaluating teclistamab, a bispecific BCMA x CD3 antibody, for the treatment of patients with relapsed and/or refractory multiple myeloma.
Recent Articles
FDA Clears Investigational New Drug Application for VOR33 in CD33-Positive AML
The U.S. Food and Drug Administration (FDA) has cleared Vor Biopharma’s Investigational New Drug (IND) application for its hematopoietic stem cell therapy VOR33. This...
Once Coronavirus Eases, Will Other Viruses Surge?
According to the Centers for Disease Control and Prevention (CDC) and other virus trackers, aside from the coronavirus, respiratory and gastrointestinal viruses are circulating...
HHS Requests COVID-19 Vaccination Data From U.S. Hospitals
Amid a slow national rollout of COVID-19 vaccines, the U.S. Department of Health and Human Services (HHS) will collect data on how many hospital...
BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma
The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...
CRISPR Gene Editing May Offer Curative Potential for Sickle Cell Disease
CRISPR-based gene editing techniques may offer curative potential for sickle cell disease (SCD) when used to target Krüppel-like factor 1 (KLF1) mutations, according to...
Current Issue
Mid-January 2021 Annual Meeting Edition
This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.